T-cell receptor recognizing SARS-CoV-2 spike-derived peptides on MHC class I (Spike-TCR)

T-cell receptors (TCRs) recognizing spike-derived peptides on MHC class I are pivotal molecules in the adaptive immune system's defense against SARS-CoV-2. These heterodimeric receptors, typically composed of alpha and beta chains, are expressed on the surface of CD8+ T cells and specifically identify viral epitopes presented by Major Histocompatibility Complex (MHC) class I molecules (Source: Nature, 2020). Upon binding to the spike-peptide-MHC complex, the TCR initiates a signaling cascade that leads to T-cell activation, the release of cytotoxic granules, and the production of antiviral cytokines such as interferon-gamma (Source: Cell, 2020). This cellular response is crucial for clearing the virus and providing long-term protection, especially as it often targets conserved regions of the spike protein that may be less prone to mutation than antibody-binding sites (Source: Science Immunology, 2021). In the pharmaceutical industry, these TCRs are being harnessed for TCR-engineered T-cell (TCR-T) therapies, where a patient's T cells are modified to express a high-affinity spike-specific TCR to treat severe COVID-19 or provide immunity to immunocompromised individuals (Source: Journal of Clinical Investigation, 2021). Understanding the repertoire and specificity of these TCRs is essential for vaccine design and the monitoring of long-term immunity (Source: Immunity, 2020).

Other names

SARS-CoV-2 spike-specific T-cell receptorSpike-reactive TCRMHC-I restricted spike TCRSARS-CoV-2 spike-specific TCR

The TCR specifically binds to SARS-CoV-2 spike protein peptide fragments presented by Major Histocompatibility Complex (MHC) class I molecules on the surface of infected cells, triggering a signaling cascade through the CD3 complex that leads to T-cell activation, the release of cytotoxic granules (perforin and granzymes), and the production of antiviral cytokines like interferon-gamma (Source: Nature, 2020; Cell, 2020).